Evidence map›Paper›PMID 40512254›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2025

[

Chia-Ju Liu, Kuan-Yin Ko, Meng-Yao Lu, Wan-Ting Hung, Shu-Wei Chou, Chia-Jui Du, Hsiu-Hao Chang, Wen-Ming Hsu, Yung-Li Yang, Yu-Ting Chien and 2 more

Registry-linked trialAbstract readComparative Study
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07195500 (the Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for the Diagnosis and Staging of Neuroblastoma and Pheochromocytoma/Paraganglioma), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07195500 recruitingnot on this map

the Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for the Diagnosis and Staging of Neuroblastoma and Pheochromocytoma/Paraganglioma

Typeobservational_patient_registrySponsorNanjing First Hospital, Nanjing Medical UniversityRan2024 to 2028Enrolled30ConditionsNeuroblastoma, Pheochromocytoma, Paraganglioma
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. hNET-targeted [Theranostics · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Chia-Ju LiuDepartment of Nuclear Medicine, National Taiwan University Hospital, Taipei, Taiwan.ORCID 0000-0003-1641-5617
Kuan-Yin KoDepartment of Nuclear Medicine, National Taiwan University Cancer Center, Taipei, Taiwan.ORCID 0000-0003-1327-9621
Meng-Yao LuDepartment of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan.ORCID 0000-0003-4461-9967
Wan-Ting HungDepartment of Surgery, National Taiwan University Hospital, Taipei, Taiwan.ORCID 0000-0002-1661-0124
Shu-Wei ChouDepartment of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan.ORCID 0000-0002-4562-6002
Chia-Jui DuDepartment of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan.ORCID 0000-0002-1715-2495
Hsiu-Hao ChangDepartment of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan.ORCID 0000-0003-1832-8509
Wen-Ming HsuDepartment of Surgery, National Taiwan University Hospital, Taipei, Taiwan.ORCID 0000-0002-5145-9538
Yung-Li YangDepartment of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan.ORCID 0000-0002-3598-7218
Yu-Ting ChienDepartment of Nuclear Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Steven Shinn-Forng PengDepartment of Nuclear Medicine, National Taiwan University Hospital, Taipei, Taiwan.ORCID 0000-0002-8177-5187
Mei-Fang ChengDepartment of Nuclear Medicine, National Taiwan University Hospital, Taipei, Taiwan. meifang@ntuh.gov.tw.ORCID 0000-0002-9359-0606

Funding

National Science and Technology Council of Taiwan 111-2314-B-002-138
6 · The paper itself

Abstract

purposeNeuroblastoma is a heterogeneous pediatric malignancy with variable imaging characteristics. Neuroblastoma tumors express SSTR receptors, but the role of [

methodsPatients with histologically confirmed neuroblastoma were prospectively recruited between September 2021 and September 2024. All participants underwent PET imaging using three radiotracers. Each modality was assessed for lesion detectability. Bone lesions were evaluated using the SIOPEN system. PET findings were interpreted as true lesions following multidisciplinary tumor board discussions and confirmed with follow-up imaging. Detectability across modalities was compared using Cochran's Q test, while maximal standardized uptake values (SUVmax) were analyzed using repeated measures ANOVA and post hoc pairwise comparisons.

resultsFifteen patients (mean age 6.1 ± 3.4; 6 females and 9 males) underwent paired PET imaging using three different radiotracers, predominantly stage M (13/15 patients) and high risk (14/15 patients). In patient-based analysis, [

conclusionThe enrichment of somatostatin receptors in neuroblastoma makes [

Indexed as

DihydroxyphenylalanineFluorodeoxyglucose F18NeuroblastomaOctreotideOrganometallic CompoundsPositron-Emission TomographyChildChild, PreschoolFemaleHumansMaleProspective Studies68Ga-octreotide, DOTA(0)-Tyr(3)-DihydroxyphenylalanineFluorodeoxyglucose F18fluorodopa F 18OctreotideOrganometallic Compounds[18F]FDG PET[18F]FDOPA PET[68Ga]Ga-DOTA-TOCNeuroblastomaPediatric oncologyPET imaging

Identifiers

PMID40512254

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.